Abstract
QT interval represents the period between the initiation of depolarization and the end of repolarization of the ventricular myocardium. Excessive prolongation of this interval may drive to a potentially fatal ventricular tachyarrhythmia known as “torsades de pointes”. Agents used to manage many endocrine disorders have been linked with QTc alterations. Among them, oral antidiabetic agents, lipid lowering and anti-obesity drugs, somatostatin analogues, thyroid and anti-thyroid agents, and adrenal steroids should be considered. Nevertheless, it is very well known that some endocrine diseases are associated with constraints in the repolarization reserve, and, as a consequence, with QTc prolongation. Besides, some disturbances in the clearance of certain drugs are more frequent in patients affected by selected endocrine entities. Taking these into account, the purpose of this article is to review the behavior of the most widely used drugs in endocrinology with regards to their potential QTc prolongation effect in human beings.
Keywords: QT interval prolongation, endocrine therapies, oral antidiabetics, thyroid drugs, HERG channel, torsades de points
Current Drug Safety
Title: Endocrine Therapies and QTc Prolongation
Volume: 5 Issue: 1
Author(s): Claudio Daniel Gonzalez, Martha de Sereday, Isaac Sinay and Silvina Santoro
Affiliation:
Keywords: QT interval prolongation, endocrine therapies, oral antidiabetics, thyroid drugs, HERG channel, torsades de points
Abstract: QT interval represents the period between the initiation of depolarization and the end of repolarization of the ventricular myocardium. Excessive prolongation of this interval may drive to a potentially fatal ventricular tachyarrhythmia known as “torsades de pointes”. Agents used to manage many endocrine disorders have been linked with QTc alterations. Among them, oral antidiabetic agents, lipid lowering and anti-obesity drugs, somatostatin analogues, thyroid and anti-thyroid agents, and adrenal steroids should be considered. Nevertheless, it is very well known that some endocrine diseases are associated with constraints in the repolarization reserve, and, as a consequence, with QTc prolongation. Besides, some disturbances in the clearance of certain drugs are more frequent in patients affected by selected endocrine entities. Taking these into account, the purpose of this article is to review the behavior of the most widely used drugs in endocrinology with regards to their potential QTc prolongation effect in human beings.
Export Options
About this article
Cite this article as:
Gonzalez Daniel Claudio, de Sereday Martha, Sinay Isaac and Santoro Silvina, Endocrine Therapies and QTc Prolongation, Current Drug Safety 2010; 5 (1) . https://dx.doi.org/10.2174/157488610789869157
DOI https://dx.doi.org/10.2174/157488610789869157 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design Lipotoxicity Disrupts Erythrocyte Function: A Perspective
Cardiovascular & Hematological Disorders-Drug Targets Function and Expression Pattern of Nonsyndromic Deafness Genes
Current Molecular Medicine Chromogranins and Inositol 1,4,5-Trisphosphate-Dependent Ca2+-Signaling in Cardiomyopathy and Heart Failure
Current Medicinal Chemistry Intensive Glucose Control in Diabetics with an Acute Myocardial Infarction Does not Improve Mortality and Increases Risk of Hypoglycemia-A Meta-Regression Analysis
Current Vascular Pharmacology Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Evaluation of the Antioxidant and Antidiabetic Potential of the Poly Herbal Formulation: Identification of Bioactive Factors
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry Tissue Engineering and Regenerative Medicine Potentialities of Materials - Based Novel Constructs - A Review
Current Regenerative Medicine (Discontinued) A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters A Survey on Left Ventricle Segmentation Techniques in Cardiac Short Axis MRI
Current Medical Imaging The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy Editorial (Thematic Issue: Measuring Myocyte Oxidative Stress and Targeting Cytokines to Evaluate Inflammatory Response and Cardiac Repair after Myocardial Infarction)
Current Vascular Pharmacology Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design